(Total Views: 551)
Posted On: 05/04/2020 7:02:18 PM
Post# of 154012
Yeah, I saw that earlier today.
Not sure remdesivir pricing (beyond their existing inventory) will be settled before we (hopefully) receive FDA approval.
However, in some respects, it may be to our advantage if this pricing metric is established in advance of us entering the market. To be sure, this is a 'hot button topic', and it may be better to not go first.
Of course, it could also work against us, as Gilead can probably afford to sell remdesivir as a loss leader because they are so big, and because the drug possibly has little commercial value other than this indication. And I use the reference "this indication" very loosely, as most thinking people would agree that it actually has no real efficacy for COVID.
I view remdesivir as a drug that was approved for the sole purpose of deceiving the American public into thinking it is safe to return to work and contribute to the GDP.
Not sure remdesivir pricing (beyond their existing inventory) will be settled before we (hopefully) receive FDA approval.
However, in some respects, it may be to our advantage if this pricing metric is established in advance of us entering the market. To be sure, this is a 'hot button topic', and it may be better to not go first.
Of course, it could also work against us, as Gilead can probably afford to sell remdesivir as a loss leader because they are so big, and because the drug possibly has little commercial value other than this indication. And I use the reference "this indication" very loosely, as most thinking people would agree that it actually has no real efficacy for COVID.
I view remdesivir as a drug that was approved for the sole purpose of deceiving the American public into thinking it is safe to return to work and contribute to the GDP.
(3)
(0)
